PathAI

We’re harnessing the power of AI to improve the diagnosis and treatment of ulcerative colitis. Learn about our new collaboration with PathAI in our latest Impact Report. https://bit.ly/4jqfRou

#ICYMI: Last week, we joined forces with Discovery Life Sciences to advance biospecimen analysis, combining our AI-powered pathology solutions with Discovery’s extensive biospecimen and biomarker services. This marks the first large-scale #AI-powered biospecimen solution in a leading commercial biobank, enabling deeper insights into translational research and accelerating the development of precision medicine. Read more about this exciting collaboration in GenomeWeb: https://lnkd.in/e97w_h49 #CancerResearch #PrecisionMedicine #DigitalPathology #Biomarkers

💬 "Mash-Tag Annual Conference is one of those unique opportunities where academics and industry can get together in a room and have conversations that push the envelope of where the field is, where it’s going, and how we can all be a part of that." - Christina Jayson, Ph.D. This past month, we traveled to the snowy peaks of Park City for MASH Tag 2025, a one-of-a-kind event where academics and industry leaders come together to tackle the biggest challenges in #MASH and #liverdisease research. We caught up with Christina Jayson, PathAI’s lead for Product in MASH, IBD, and Immunology and Inflammation, who offered unique insights into the field’s direction. Read her recap for the conference and understand how #AIPathology can play a pivotal role in #MASH research and clinical research. #Biotech #ClinicalTrials #Pathology #DigitalPathology #biopharma #drugdevelopment #biomarker #biomarkerdiscovery

We are excited to announce our strategic partnership with PathAI to introduce the first large-scale AI-powered biospecimen solutions. This collaboration will enable us to offer enhanced digital and quantitative biospecimen insights using artificial intelligence. Read the press release: https://lnkd.in/gFTvKY7g By deploying PathAI’s AISight® Image Management System, ArtifactDetect, and TumorDetect products, we will integrate AI technologies into our global biospecimen operations to automate routine pathology tasks and save valuable time for our pathologists, allowing them to focus on more complex cases. “Integrating PathAI’s advanced AI technology aligns perfectly with our commitment to providing our customers with the highest quality and most comprehensive data and insights from their biospecimens investment,” said Greg Herrema, CEO of Discovery. “This partnership will significantly enhance our ability to deliver precise, reliable, and timely insights, ultimately advancing the discovery and development of therapies and diagnostics that improve patient outcomes.” This partnership marks a major milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.

We’re thrilled to partner with Discovery Life Sciences to launch the first large-scale #AI-powered biospecimen solutions in a leading commercial biobank. 📝 Read the announcement: https://lnkd.in/g-p3tx3w Discovery Life Sciences will leverage PathAI’s #AISight® Image Management System, ArtifactDetect, and TumorDetect products across its biospecimens business to automate routine pathology tasks, saving time for #pathologists and enabling them to focus on complex cases. This partnership will also deliver quantitative, tissue-level insights, providing customers with standardized, high-confidence data from their biospecimens. 🤝 Together, we will develop a custom #AI-driven tissue analysis panel exclusive to Discovery, further advancing translational research and biomarker discovery for biopharma partners. The combination of PathAI’s products and Discovery’s high-quality, structured, multimodal datasets will accelerate the development of new assays and diagnostic tools, enabling improved patient outcomes more reliably and efficiently. 💬 “We are excited to partner with Discovery Life Sciences to revolutionize the biospecimens industry,” said Andrew Beck, CEO of PathAI. “Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in #pathology assessments, ultimately benefiting their customers with enhanced data quality and insights while accelerating the discovery and development of new therapies and diagnostics.” 💬 “Integrating PathAI’s advanced AI technology aligns perfectly with our commitment to providing our customers with the highest quality and most comprehensive data and insights from their #biospecimens investment,” said Greg Herrema, CEO of Discovery. “This #partnership will significantly enhance our ability to deliver precise, reliable, and timely insights, ultimately advancing the discovery and development of therapies and diagnostics that improve patient outcomes.” …………….. ArtifactDetect and TumorDetect are for research use only. Not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland. #digitalpathology #biotech #healthtech

🔬 "In the era of #precisionmedicine, the concept of matching patients to therapies based on protein and molecular #biomarkers, pathologists are now responsible for answering the question: Are there specific drugs that will be effective for this patient?" - Eric Walk MD, FCAP, PathAI Chief Medical Officer We're thrilled to share our latest Q+A with Agilent Technologies and our collaborators are now featured in Lab Manager! This piece highlights the incredible power of collaboration in advancing #pathology through AI-driven solutions. Learn how collaborations across the industry are paving the way for groundbreaking innovations that improve patient outcomes. https://lnkd.in/dZn2FgdT

🇨🇭 Grüezi aus Luzern! We were honored to participate in Brennpunkt Pathologie 2025 where our Chief Medical Officer, Eric Walk MD, FCAP, delivered an insightful presentation on “#AI Fluency in the Era of Digital & Computational #Pathology.” A big thank you to everyone who stopped by to connect with our team, including Max Zinner and Suzana Vega Harring MD MBA. We were thrilled to share how AISight® Image Management System fuels #PathologyWorkflows, enhancing efficiency and precision in #digitalpathology lab processes. 🔍 Interested in learning more? Discover AISight®: https://lnkd.in/ef5NWxse and reach out to us at digitaldx@pathai.com .............. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.

We're excited to participate in 𝐁𝐫𝐞𝐧𝐧𝐩𝐮𝐧𝐤𝐭 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐢𝐞 2025, taking place from January 16 - 17 in Lucerne, Switzerland. This “Focus on #Pathology” Symposium will feature renowned speakers as they share insights on 𝐠𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐭𝐮𝐦𝐨𝐫 𝐜𝐥𝐚𝐬𝐬𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲. Don’t miss the chance to meet with our team, Max Zinner and Suzana Vega Harring MD MBA, and discover how 𝐀𝐈𝐒𝐢𝐠𝐡𝐭® 𝐈𝐦𝐚𝐠𝐞 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐒𝐲𝐬𝐭𝐞𝐦 is revolutionizing #pathologyworkflows and enhancing case management to drive efficiency and precision in pathology lab processes. Learn more about 𝐀𝐈𝐒𝐢𝐠𝐡𝐭®: https://lnkd.in/ef5NWxse 𝘈𝘐𝘚𝘪𝘨𝘩𝘵® 𝘪𝘴 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚; 𝘈𝘐𝘚𝘪𝘨𝘩𝘵® 𝘋𝘹 𝘪𝘴 𝘊𝘌-𝘐𝘝𝘋 𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘌𝘌𝘈, 𝘜𝘒, 𝘢𝘯𝘥 𝘚𝘸𝘪𝘵𝘻𝘦𝘳𝘭𝘢𝘯𝘥. #BrennpunktPathologie2025 #PathAI #DigitalPathology #AIPoweredHealthcare #AnatomicPathology

We had an incredible opportunity to attend and present at Mash-Tag Annual Conference, where PathAI joined a community of researchers, clinicians, and industry leaders dedicated to advancing the diagnosis and treatment of Metabolic-Associated Steatohepatitis (MASH) and liver fibrosis. The event fostered invaluable collaboration and conversation, from identifying patient populations to refining therapeutic endpoints, as we work together to transform care for #MASH patients. #Pathology #AIPathology #healthtech #LiverDisease #Fibrosis #ClinicalTrials

Tomorrow, PathAI CEO Andrew Beck will present groundbreaking data from our recent #NatureMedicine publications at #MASHTAG2025! These studies highlight the clinical validation of AI-powered tools like AIM-MASH and their transformative potential in improving enrollment criteria and #endpoint assessments for #MASH clinical trials. Catch Andy's session, "Can #DigitalPathology Save MASH #ClinicalTrials?" on Saturday, January 11th, at 9:00 AM. Discover how AISight®, Liver Explore™, and AIM-MASH are revolutionizing the field of pathology, offering scalable, reproducible, and innovative solutions for MASH research. 📚 Read the publications 1. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis: https://lnkd.in/gez_4SgK 2. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases: https://lnkd.in/gaiqqeUx #LiverDisease #AIPathology #pathology #healthtech #biotech ......................... Liver Explore™ and AIM-MASH are for research use only. Not for use in diagnostic procedures. AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland.